NCT06861894View on ClinicalTrials.gov

Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2029

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Adebrelimab and nab-paclitaxel and carboplatin

Adebrelimab combined with nab-paclitaxel and carboplatin as neoadjuvant therapy

RADIATION

Radiation

concurrent chemoradiotherapy

PROCEDURE

standard oesophagectomy

standard oesophagectomy

OTHER

active surveillance

active surveillance

Trial Locations (1)

Unknown

Shanghai Chest Hospital, Shanghai

All Listed Sponsors
lead

Zhigang Li

OTHER